Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Microdosing

The practice of taking sub-perceptual doses of psychedelics, and the evidence on whether measurable effects follow.

State of the evidence

Synthesized

Synthesized from 18 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Microdosing, micro-dosing, sub-perceptual dosing, low-dose psychedelics, then ranked by relevance.

The evidence on psychedelic microdosing is mixed and inconclusive. While observational and survey studies report subjective improvements in mood, cognition, and well-being, the few placebo-controlled trials find that these benefits are largely explained by the placebo effect and positive expectancy. The most rigorous meta-analyses show no significant mood benefits and a small decrease in cognitive control, indicating that any positive effects are not robustly supported by controlled research.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Self-blinding citizen science to explore psychedelic microdosing. 2021
No effect

All psychological outcomes improved from baseline in both microdose and placebo groups, with no significant between-group differences, suggesting anecdotal benefits are due to placebo.

RCT (self-blinding citizen science) Sample size: 191

Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting 2018
Supports

Provided quantitative support for cognitive-enhancing properties of microdosing, but authors caution that future placebo-controlled designs are needed to confirm preliminary findings.

observational (open-label natural setting)

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing 2021
Mixed

Found increased well-being and reduced anxiety/depression at 4 weeks, but positive expectancy at baseline predicted improvements, indicating a significant placebo response.

prospective observational Sample size: 81

Motives and Side-Effects of Microdosing With Psychedelics Among Users 2019
Supports

Performance enhancement was the main motive (37%), and most reported negative effects were psychological and acute; majority were unaware of exact dose consumed.

observational (online survey) Sample size: 1116

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study 2022
No effect

Acute effects were more intense for active dose only in participants who correctly identified their condition; no effects on creativity or cognition, with small changes toward cognitive impairment.

RCT (double-blind placebo-controlled) Sample size: 34

Psychedelic microdosing benefits and challenges: an empirical codebook 2019
Unclear

Summarized experiences from the microdosing community to identify high-potential targets for future research, without quantitative effect estimates.

qualitative (mixed-methods codebook)

Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. 2019
Supports

Reported improvements in negative moods (especially depression), positive moods, energy, work effectiveness, and health habits; also alleviation of symptoms in various conditions.

observational (descriptive reports) Sample size: 1000

Psychedelic Microdosing: A Subreddit Analysis 2019
Mixed

Motivations included mental health self-management and cognitive enhancement; benefits reported included improved mood and creativity, but limitations included adverse effects, lack of improvement, and concerns about dependence.

observational (content analysis of Reddit)

Psychedelic Microdosing: Prevalence and Subjective Effects 2020
Supports

Microdosers attributed improvements in mood, anxiety, memory, attention, and sociability; common reasons for quitting were legal risks and difficulty obtaining substances.

observational (online survey) Sample size: 2347

The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field 2022
Mixed

Studies showed wide risk of bias; laboratory studies found changes in pain perception, time perception, and neurophysiology; self-report studies found changes in cognition and mental health; claims that effects are largely due to expectancy are premature.

systematic review

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis 2026
No effect

The only significant pooled effect was a small decrease in cognitive control (d = -0.34); all other domains (including mood) were non-significant, with narrative evidence suggesting self-reported mood benefits are likely expectancy-driven.

umbrella review with narrative synthesis Sample size: 1614

Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States 2026
Mixed

26.5% of lifetime psychedelic users had microdosed; microdosing was associated with more anxiety symptoms and adverse childhood events, and motives varied by demographics and mental health.

observational (cross-sectional survey)

Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use 2026
Unclear

Argues that microdosing is not a single phenomenon and must be classified by substance class, dose-response, and evidence level; no quantitative effect estimates provided.

review (conceptual and comparative)

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series 2026
Supports

Clinical improvements were observed following an integrative iboga microdosing protocol with psychotherapy, but the design precludes causal inference.

case series Sample size: 3

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey. 2026
Unclear

Provided prevalence data on microdosing for psilocybin, LSD, and MDMA; no effect estimates reported.

observational (nationally representative survey)

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026
No effect

Chronic psilocin microdosing did not affect locomotor activity, depressive-like behavior, sociability, novelty seeking, or dentate gyrus cell proliferation.

preclinical (animal study)

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT 2026
No effect

Psilocybin microdosing was associated with subtle EEG changes (reduced global field power, frequency-specific alterations) but no significant broadband spatiotemporal changes, indicating limited brain effects.

observational (EEG study)

A New Use for an Old Compound: Microdosing LSD to Reduce Fibromyalgia Symptoms 2026
Supports

Microdosed LSD improved pain-related behaviors and facial expressions in a sex- and route-dependent manner in a mouse model of fibromyalgia.

preclinical (animal study)

Points of agreement

  • Observational and survey studies consistently report subjective improvements in mood, well-being, and cognition from microdosing.
  • Placebo-controlled trials consistently find no significant differences between microdose and placebo groups on most outcomes.
  • Positive expectancy and placebo effects are consistently identified as major confounds across multiple study designs.
  • The most rigorous meta-analyses find no significant mood benefits and a small negative effect on cognitive control.

Conflicts

  • Observational studies report positive effects on mood and cognition, while placebo-controlled RCTs find null or expectancy-driven effects.
  • Some studies (e.g., 16309, 25833) report broad benefits, whereas others (e.g., 19853, 27727) find no effects or slight impairment.
  • The systematic review (25852) argues that expectancy explanations are premature, while the umbrella review (27669) and RCTs (15941, 17432) emphasize placebo/expectancy as the primary driver.

Gaps

  • Durability of effects beyond 4 weeks is not studied in controlled designs.
  • Blinding integrity is rarely assessed and often broken, confounding results.
  • Dose standardization and substance purity are lacking in most naturalistic studies.
  • Representative population samples are missing; most studies rely on self-selected, online convenience samples.
  • Preclinical evidence is limited and does not support behavioral or neurogenic effects.
  • No large, multi-site, fully blinded RCTs with adequate sample sizes have been conducted.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Microdosing, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Microdosing or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: June 2026 →

457 articles · 176 from the last two years · 88,109 participants across 173 studies reporting sample size

Common study designs

review 85 case study 19 cross-sectional survey 20 randomized controlled trial 38 theoretical or philosophical paper 19

Research

Synthesize the evidence → Search all →

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, biochemistry, and behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Chronic microdosing of psilocin (0.05 or 0.075 mg/kg) in adult male Wistar rats over five weeks did not alter locomotor activity, depressive-like behavior, sociability, or novelty seeking, and did not increase cell proliferation in the dentate gyrus of the hippocampus. A small anxiogenic effect was detected in the Elevated Plus Maze. The findings suggest that, under this dosing schedule, psilocin microdosing produces limited behavioral effects and does not enhance hippocampal progenitor proliferation.

DOI: 10.1016/j.pbb.2026.174231 (opens in new tab) Full text (opens in new tab) Anxiety Depression Behavioral testing Hippocampal neurogenesis +3

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis

Journal of Psychopharmacology June 28, 2026 Yiğit Özaydın, Buket Canlan Özaydın

An umbrella review of systematic reviews and meta-analyses on psychedelic microdosing (repeated low doses of LSD or psilocybin) for mood and cognitive effects found that the only statistically significant pooled result was a small decrease in cognitive control, contrary to popular claims of enhancement. Self-reported mood benefits were largely not replicated under placebo-controlled conditions, suggesting expectancy effects. Short-term tolerability was acceptable, but cardiovascular signals and long-term risks remain uncharacterized. The evidence base is limited by high overlap among primary studies and methodological heterogeneity.

DOI: 10.1177/02698811261456196 (opens in new tab) Psilocybin Mood Cognition Expectancy theory +6

Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States

Journal of Psychoactive Drugs June 19, 2026 Carla J. Berg, Darcey M. Mccready, Cassidy R Loparco et al.

Among a sample of young adults with high rates of past-month cannabis use, lifetime and past-year psychedelic use were 27.7% and 11.9%, respectively, with psilocybin/amanita, MDMA, and LSD being most common. Nearly half used psychedelics only for nonmedical purposes. Of those who had ever used, 26.5% had microdosed. Older age, male sex, Black race, metropolitan residence, more depressive symptoms, and more adverse childhood events were linked to lifetime use. Microdosing was associated with not having children, more anxiety, and more adverse childhood events. Mental health symptoms and adverse childhood events were also tied to higher use motives, including expansion, mood enhancement, and symptom management.

DOI: 10.1080/02791072.2026.2685527 (opens in new tab) Addiction Young adult Product mathematics Substance use +2

Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use

Journal of Advances in Developmental Research June 18, 2026 Eric P. Rubenstein

The term 'microdosing' is often treated as a single phenomenon, but it actually describes a low-dose pattern applied across many substances with different mechanisms, effects, and risks. This conceptual review classifies psychedelic and psychedelic-adjacent substances—including classical psychedelics, dissociatives, empathogens, and natural compounds—by therapeutic plausibility, pharmacological mechanism, dose-response, perceptibility, tolerance, neuroplasticity, context, and evidence strength. The article argues that without separating these factors, microdosing research cannot yield interpretable or scientifically meaningful conclusions.

DOI: 10.71097/ijaidr.v17.i1.1997 (opens in new tab) Full text (opens in new tab) Anxiety Psychoactive substance Psychoactive drug Hallucinogen +7

PK and PK / PD Modeling of Bcl2 Inhibitor S65487 in Patients With AML and Investigation of Nonlinearity With Microdosing

CPT Pharmacometrics & Systems Pharmacology June 17, 2026 Chloé Burlot, François Riglet, Mathilde Romagnoli et al.

S65487, a drug targeting the Bcl2/Bim protein complex implicated in cancer cell survival, was studied using pharmacokinetic/pharmacodynamic modeling. At a 1200 mg dose, simulations predicted a 97.6% maximum reduction in the formation of the Bcl2/Bim complex. A microdose study in healthy volunteers showed substantially different pharmacokinetic parameters compared to therapeutic doses in cancer patients, indicating slightly nonlinear drug behavior. The most plausible explanation was nonlinearity in drug disposition, modeled via a Michaelis-Menten approximation of target-mediated drug disposition. This optimized model reduced the discrepancy in describing microdose exposure from 5-fold to 1-fold, without affecting therapeutic dose descriptions, enabling better extrapolation from microdose to therapeutic dose results.

DOI: 10.1002/psp4.70288 (opens in new tab) Microdose Pharmacokinetics Population Therapeutic index +7

Sustained Low-Dose Semaglutide Is Linked to Broad-Spectrum Cardiometabolic Benefits, and Better Tolerability Profile over Low-Dose Tirzepatide, Motivating Semaglutide Microdosing Studies

Preprints.org June 9, 2026 Karthik Murugadoss, A.J. Venkatakrishnan, Venky Soundararajan preprint

In routine care, many patients taking semaglutide or tirzepatide do not reach recommended maintenance doses. Using electronic health records from 29 million patients, researchers identified 814 individuals who sustained very low doses of semaglutide (0.25 mg) or tirzepatide (2.5 mg) for at least six months. Over 24 months, low-dose tirzepatide showed a worse adverse event profile than low-dose semaglutide, including higher rates of constipation (32.6% vs 22.4%), acute kidney injury (2.7% vs 0.4%), and muscle cramps (8.3% vs 4%). Low-dose tirzepatide also led to greater weight loss. Low-dose semaglutide was associated with broad cardiometabolic benefits despite minimal weight change, and better tolerability than low-dose tirzepatide.

DOI: 10.20944/preprints202606.0636.v1 (opens in new tab) Semaglutide Adverse effect Tolerability Clinical trial +4

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series

Frontiers in Pharmacology June 3, 2026 Burton J. Tabaac, Robin Carhart-Harris, Teresa Yung

Three individuals with persistent symptoms after traumatic brain injury or hypoxic-ischemic brain injury completed a six-week protocol combining a participant-directed iboga-containing microdosing regimen (using whole root bark biomass with about 3.845% ibogaine content, yielding an estimated 3.8–38.5 mg/day ibogaine equivalent) with weekly Accelerated Experiential Dynamic Psychotherapy and supportive nutraceuticals. All three showed progressive neurological recovery; two reported complete symptom remission at long-term follow-up. Participants discontinued all prescription medications and reported resolution of headaches, brain fog, fatigue, irritability, and mood swings, with a return to regular activities and renewed enthusiasm. The authors note that the findings do not establish causality or iboga-specific efficacy due to the multimodal intervention and methodological limitations.

DOI: 10.3389/fphar.2026.1840956 (opens in new tab) Traumatic brain injury Mood Therapeutic effect Depression economics +7

Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine–Naloxone With a Focus on the Unhoused Population

The Journal of Clinical Pharmacology June 1, 2026 David F. Lehmann, Olivia Tanner, Eliesha Pepple et al.

Expanding buprenorphine-naloxone treatment to marginalized groups, including unhoused people, is a priority but is hindered by fear of precipitating opioid withdrawal. Microdosing methods during the first week of treatment avoid requiring opioid abstinence and do not cause withdrawal. This review explains the scientific basis for microdosing, centered on the pharmacodynamic principle of pseudo-irreversibility for a partial agonist like buprenorphine.

DOI: 10.1002/jcph.70213 (opens in new tab) Full text (opens in new tab) Clinical pharmacology Abstinence Population Clinical trial +6

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.

Rand health quarterly June 1, 2026 M. Priest, B. Kilmer, Ben Senator et al.

Use of psychedelic substances is becoming more common in the U.S., with several states considering policies to decriminalize or legalize them for nonmedical use. Survey data on 11 psychedelic substances show that microdosing—taking a small, sub-hallucinogenic dose on a regular schedule—is a prevalent practice, especially for psilocybin, LSD, and MDMA. The findings provide new information to inform policy debates about alternatives to prohibition.

DOI: 10.7249/rhq-13-03-02 (opens in new tab) Full text (opens in new tab) Medicine Psychology

Clinical trials

All Microdosing trials →